Bare-metal Stents(BMS) Versus Drug-eluting Stents(DES) in Patients Who Underwent Periprocedural Blood Transfusion : A Nationwide Longitudinal Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 28,322
- 试验地点
- 1
- 主要终点
- Incidence density of MACE (Major adverse clinical events)
研究概览
简要总结
Retrospective cohort study of Korean National Healthcare Insurance Database. To investigate clinical outcomes of bare metal stents versus drug eluting stents in patients who underwent periprocedural red blood cell transfusion.
详细描述
A Korean nationwide, multi-center, retrospective observational cohort study.
The receipt of red blood cell transfusion is at high risk of cardiac events or death. But little is know regarding the comparative outcomes of BMS and DES implantation in patients who underwent periprocedural red blood cell transfusion.
Longitudinal data is collected from administrative claims in the national health insurance services of Korea. All Korean data(N=500,591) undergoing PCI from 2006 to 2015 is extracted. BMS or DES Patients(N=28,322) who received periprocedural red blood cell transfusion is investigate. Clinical outcomes until December 31, 2017 is investigate.
Primary endpoint is a time to the first major adverse clinical event(MACE) defined as a composite of all-cause death, revascularization, critically ill cardiovascular status, or stroke.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with percutaneous coronary intervention from 2006 to 2015
- •Patients with the implantation of BMS or DES
- •Patients with the receipt of periprocedural red blood cell transfusion
排除标准
- •Patients without any of stent implantation
结局指标
主要结局
Incidence density of MACE (Major adverse clinical events)
时间窗: 1 year
The first major adverse clinical event(MACE) defined as a composite of all-cause death, revascularization, critically ill cardiovascular status, and stroke.
次要结局
未报告次要终点
研究者
Jin-Ho Choi
MD, PhD, Professor, Principal Investigator
Samsung Medical Center